Skip to NavigationSkip to content


NICE recommends Daiichi’s Lixiana for blood clots

Daiichi Sankyo
Daiichi has earned NICE approval for its newly-launched drug Lixiana

Daiichi Sankyo has won a speedy approval from NICE, after the NHS guidance body approved its newly-launched blood clotting drug Lixiana as a treatment for clots in the legs and lungs.

The NICE decision comes just days after Daiichi launched Lixiana (edoxaban) in the UK, and shortly after the Japanese firm earned European approval for the prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults and the prevention of stroke and clots in adults with

Anti-blood clotting drug Eliquis gets NICE nod

Eliquis image

Bristol-Myers Squibb and Pfizer’s Eliquis for preventing blood clots has been shown the green light to treat venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism in adults.

NICE has given Eliquis (apixaban) final draft guidance to treat the conditions on the NHS that can result in long-term illness, including chronic pain, swelling and skin changes in affected limbs.

Pfizer/BMS blood thinner gains new licence

eliquis image

Pfizer and Bristol-Myers Squibb have been handed a much-needed lift after its new blood thinner Eliquis gained a licence extension in the US today.

The drug has been approved by the FDA for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) – i.e., clots in the legs and lungs. It now also can be used for the reduction in the risk of recurrent DVT and PE following initial therapy.

Pradaxa gets DVT indication

Pradaxa image

Pradaxa has been given approval in Europe to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) just a week after Boehringer Ingelheim paid out $650 million to settle US legal battles over the blood-thinner.

Boehringer made its settlement to bring to an end to 4,000 lawsuits which have been brought against the company in the US over Pradaxa (dabigatran etexilate).

Edoxaban ‘as effective as warfarin’

Daiichi Sankyo image

Daiichi Sankyo is celebrating after its once-a-day blood thinner edoxaban proved as effective as warfarin in a late-stage trial, although it faces stiff competition from recently-launched rivals.

It is a potentially lucrative market, with relatively new treatments - such as Bayer’s Xarelto and Boehringer Ingelheim’s Pradaxa - set to make $10 billion as replacements for warfarin, which has been in common use for decades but which requires careful monitoring.

Eliquis poised for new US approval

Eliquis image

Pfizer and Bristol-Myers Squibb have submitted their oral direct Factor Xa inhibitor Eliquis to the FDA to prevent deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have had a hip or knee replaced.

The US regulator aims to make a decision by 15 March next year and, if approved in this indication, it will bring Eliquis (apixaban) onto a par with its status in Europe.

Taken twice a day, the drug targets a key blood-clotting protein to prevent clots forming.

VTE boost for Eliquis

eliquis image

Bristol-Myers Squibb and Pfizer’s oral blood thinner Eliquis is as efficient as standard of care and causes less bleeding in patients with acute venous thromboembolism (VTE), according to a new analysis from the companies.

Eliquis (apixaban) on its own was non-inferior to the current standard of care - initial parenteral enoxaparin treatment overlapped with warfarin therapy - in treating the two VTE conditions: symptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE) in the six-month Phase III AMPLIFY trial.

Xarelto gets new EU approval

Xarelto image

Bayer’s oral anticoagulant Xarelto has extended its licence in Europe to treat pulmonary embolism (PE) and prevent recurrent deep vein thrombosis (DVT) in adults.

The European Commission’s move mirrors that by the FDA earlier this month, when the US regulator similarly expanded Xarelto (rivaroxaban)’s indications.

PE happens when a blood clot in the leg or pelvis travels to the lung via the heart: if it blocks one of the pulmonary arteries, death is likely to result without rapid treatment.

NICE yes for Xarelto to treat blood clots

Xarelto image

NICE is recommending Bayer’s Xarelto (rivaroxaban) for the treatment and prevention of deep vein thrombosis (DVT).

The watchdog said in its final guidance that Xarelto is now an option for treating deep vein thrombosis and preventing recurrent deep vein thrombosis and pulmonary embolism in adults diagnosed with acute DVT.

NICE recommends Xarelto for stroke prevention

Xarelto picture

NICE is recommending Bayer’s anticoagulant pill Xarelto to help reduce the risk of stroke in certain patients. 

The watchdog’s final guidance recommends Xarelto (rivaroxaban), a Factor Xa inhibitor, as an option for the prevention of stroke and systemic embolism in people with atrial fibrillation. 

Its licence is specifically for patients with non-valvular atrial fibrillation who have one or more risk factors such as congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, prior stroke or transient ischaemic attack. 

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches